Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo

Cancer Letters

Volumn 302, Issue 1, 2011, Pages 11-19

  Zhang, Chong ^a   Wu, Rui ^a   Zhu, Hong ^a   Hu, Yong zhou ^a   Jiang, Hai ^b   Lin, Neng ming ^c   He, Qiao jun ^a   Yang, Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

CA 4; Combination therapy; NF B; TRAIL Apo 2L

Indexed keywords

CASPASE; COMBRETASTATIN A4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; CYTOPLASM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HCT116 CELLS; HUMANS; IMMUNOBLOTTING; MICE; MICE, NUDE; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN TRANSPORT; STILBENES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 79251596643     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.12.001     Document Type: Article

References (47)

1. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Stratford M.R., Dennis M.F., Chaplin D.J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999, 59:1626-1634.
2. Zhu H., Zhang J., Xue N., Hu Y., Yang B., He Q. Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells. Invest. New Drugs 2010, 28:493-501.
3. Dorr R.T., Dvorakova K., Snead K., Alberts D.S., Salmon S.E., Pettit G.R., phosphate Antitumor activity of combretastatin-A4 a natural product tubulin inhibitor. Invest. New Drugs 1996, 14:131-137.
4. Boehle A.S., Sipos B., Kliche U., Kalthoff H., Dohrmann P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann. Thorac. Surg. 2001, 71:1657-1665.
5. Wu R., Ding W., Liu T., Zhu H., Hu Y., Yang B., He Q. XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro. Cancer Lett. 2009, 285:13-22.
6. Hori K., Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Brit. J. Cancer 2003, 89:1334-1344.
7. Hori K., Saito S. Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700). Brit. J. Cancer 2004, 90:549-553.
8. Simoni D., Romagnoli R., Baruchello R., Rondanin R., Grisolia G., Eleopra M., Rizzi M., Tolomeo M., Giannini G., Alloatti D., Castorina M., Marcellini M., Pisano C. Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity. J. Med. Chem. 2008, 51:6211-6215.
9. Rustin G.J., Galbraith S.M., Anderson H., Stratford M., Folkes L.K., Sena L., Gumbrell L., Price P.M. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 2003, 21:2815-2822.
10. McKeage M.J., Baguley B.C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010, 116:1859-1871.
11. Wang S., El-Deiry W.S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003, 22:8628-8633.
12. Koschny R., Walczak H., Ganten T.M. The promise of TRAIL--potential and risks of a novel anticancer therapy. J. Mol. Med. 2007, 85:923-935.
13. Zhu H., Ding W.J., Wu R., Weng Q.J., Lou J.S., Jin R.J., Lu W., Yang B., He Q.J. Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest. 2010, 28:23-32.
14. Dejosez M., Ramp U., Mahotka C., Krieg A., Walczak H., Gabbert H.E., Gerharz C.D. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ. 2000, 7:1127-1136.
15. Chen X., Thakkar H., Tyan F., Gim S., Robinson H., Lee C., Pandey S.K., Nwokorie C., Onwudiwe N., Srivastava R.K. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001, 20:6073-6083.
16. White-Gilbertson S., Mullen T., Senkal C., Lu P., Ogretmen B., Obeid L., Voelkel-Johnson C. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene 2009, 28:1132-1141.
17. Cuello M., Ettenberg S.A., Nau M.M., Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol. 2001, 81:380-390.
18. Ray S., Shyam S., Fraizer G.C., Almasan A. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol. Cancer Ther. 2007, 6:1368-1378.
19. Dejardin E., Deregowski V., Chapelier M., Jacobs N., Gielen J., Merville M.P., Bours V. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 1999, 18:2567-2577.
20. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
21. Nguyen T., Zhang X.D., Hersey P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin. Cancer Res. 2001, 7:966s-973s.
22. Strater J., Hinz U., Walczak H., Mechtersheimer G., Koretz K., Herfarth C., Moller P., Lehnert T. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer Res. 2002, 8:3734-3740.
23. Hayakawa M., Miyashita H., Sakamoto I., Kitagawa M., Tanaka H., Yasuda H., Karin M., Kikugawa K. Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J. 2003, 22:3356-3366.
24. Hansen S.K., Baeuerle P.A., Blasi F. Purification, reconstitution, and I kappa B association of the c-Rel-p65 (RelA) complex, a strong activator of transcription. Mol. Cell Biol. 1994, 14:2593-2603.
25. Weizman A.V., Nguyen G.C. Colon cancer screening in 2010: an up-date. Miner. Gastroenterol. Dietol. 2010, 56:181-188.
26. Holt P.R., Kozuch P., Mewar S. Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. Best Pract. Res. Clin. Gastroenterol. 2009, 23:889-907.
27. Zhu H., Liu X.W., Ding W.J., Xu D.Q., Zhao Y.C., Lu W., He Q.J., Yang B. Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett. 2010, 297:155-164.
28. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277:815-818.
29. Schneider P., Thome M., Burns K., Bodmer J.L., Hofmann K., Kataoka T., Holler N., Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997, 7:831-836.
30. Elrod H.A., Sun S.Y. Modulation of death receptors by cancer therapeutic agents. Cancer Biol. Ther. 2008, 7:163-173.
31. Eikesdal H.P., Bjerkvig R., Mella O., Dahl O. Combretastatin A-4 and hyperthermia: a potent combination for the treatment of solid tumors. Radiother. Oncol. 2001, 60:147-154.
32. Grosios K., Loadman P.M., Swaine D.J., Pettit G.R., Bibby M.C. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 2000, 20:229-233.
33. West C.M., Price P. Combretastatin A4 phosphate. Anticancer Drugs 2004, 15:179-187.
34. Rustin G.J., Shreeves G., Nathan P.D., Gaya A., Ganesan T.S., Wang D., Boxall J., Poupard L., Chaplin D.J., Stratford M.R., Balkissoon J., Zweifel M. A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Brit. J. Cancer 2010, 102:1355-1360.
35. Bilenker J.H., Flaherty K.T., Rosen M., Davis L., Gallagher M., Stevenson J.P., Sun W., Vaughn D., Giantonio B., Zimmer R., Schnall M., O'Dwyer P.J. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin. Cancer Res. 2005, 11:1527-1533.
36. Goke R., Goke A., Goke B., Chen Y. Regulation of TRAIL-induced apoptosis by transcription factors. Cell Immunol. 2000, 201:77-82.
37. Tran S.E., Holmstrom T.H., Ahonen M., Kahari V.M., Eriksson J.E. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 2001, 276:16484-16490.
38. Wang X., Chen W., Zeng W., Bai L., Tesfaigzi Y., Belinsky S.A., Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol. Cancer Ther. 2008, 7:1156-1163.
39. Ricci M.S., Kim S.H., Ogi K., Plastaras J.P., Ling J., Wang W., Jin Z., Liu Y.Y., Dicker D.T., Chiao P.J., Flaherty K.T., Smith C.D., El-Deiry W.S. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007, 12:66-80.
40. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
41. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
42. Micheau O., Lens S., Gaide O., Alevizopoulos K., Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol. Cell Biol. 2001, 21:5299-5305.
43. Thanos D., Maniatis T. NF-kappa B: a lesson in family values. Cell 1995, 80:529-532.
44. Khanbolooki S., Nawrocki S.T., Arumugam T., Andtbacka R., Pino M.S., Kurzrock R., Logsdon C.D., Abbruzzese J.L., McConkey D.J. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 2006, 5:2251-2260.
45. Tozer G.M., Akerman S., Cross N.A., Barber P.R., Bjorndahl M.A., Greco O., Harris S., Hill S.A., Honess D.J., Ireson C.R., Pettyjohn K.L., Prise V.E., Reyes-Aldasoro C.C., Ruhrberg C., Shima D.T., Kanthou C. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res. 2008, 68:2301-2311.
46. Grunstein J., Roberts W.G., Mathieu-Costello O., Hanahan D., Johnson R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 1999, 59:1592-1598.
47. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.